Published in Cancer Res on June 15, 2010
The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings. Mol Oncol (2011) 2.52
Nonhomologous end joining drives poly(ADP-ribose) polymerase (PARP) inhibitor lethality in homologous recombination-deficient cells. Proc Natl Acad Sci U S A (2011) 2.47
Homologous recombination and its regulation. Nucleic Acids Res (2012) 2.44
Synergistic inhibition of hepatocellular carcinoma growth by cotargeting chromatin modifying enzymes and poly (ADP-ribose) polymerases. Hepatology (2012) 2.23
Harnessing synthetic lethal interactions in anticancer drug discovery. Nat Rev Drug Discov (2011) 2.01
Mechanisms of resistance to therapies targeting BRCA-mutant cancers. Nat Med (2013) 1.94
Human RecQ helicases in DNA repair, recombination, and replication. Annu Rev Biochem (2014) 1.68
Evaluation of candidate biomarkers to predict cancer cell sensitivity or resistance to PARP-1 inhibitor treatment. Cell Cycle (2012) 1.50
PTEN deletion in prostate cancer cells does not associate with loss of RAD51 function: implications for radiotherapy and chemotherapy. Clin Cancer Res (2011) 1.46
Poly (ADP-ribose) polymerase inhibitors: recent advances and future development. J Clin Oncol (2015) 1.41
PARP-1 and PARP-2: New players in tumour development. Am J Cancer Res (2011) 1.23
Synthetic lethal approaches to breast cancer therapy. Nat Rev Clin Oncol (2010) 1.17
PARP inhibitors in the management of breast cancer: current data and future prospects. BMC Med (2015) 1.16
The Elephant and the Blind Men: Making Sense of PARP Inhibitors in Homologous Recombination Deficient Tumor Cells. Front Oncol (2013) 1.10
Response of human prostate cancer cells and tumors to combining PARP inhibition with ionizing radiation. Mol Cancer Ther (2011) 1.08
A fine-scale dissection of the DNA double-strand break repair machinery and its implications for breast cancer therapy. Nucleic Acids Res (2014) 1.05
BRCA1, PARP, and 53BP1: conditional synthetic lethality and synthetic viability. J Mol Cell Biol (2011) 1.02
RECQ1 plays a distinct role in cellular response to oxidative DNA damage. DNA Repair (Amst) (2012) 1.00
ARTD1/PARP1 negatively regulates glycolysis by inhibiting hexokinase 1 independent of NAD+ depletion. Cell Rep (2014) 1.00
Enhancement of synthetic lethality via combinations of ABT-888, a PARP inhibitor, and carboplatin in vitro and in vivo using BRCA1 and BRCA2 isogenic models. Mol Cancer Ther (2012) 1.00
Resistance to PARP-Inhibitors in Cancer Therapy. Front Pharmacol (2013) 0.99
The Promise of Proteomics for the Study of ADP-Ribosylation. Mol Cell (2015) 0.98
Glioblastoma cells containing mutations in the cohesin component STAG2 are sensitive to PARP inhibition. Mol Cancer Ther (2013) 0.93
Hyperactivation of PARP triggers nonhomologous end-joining in repair-deficient mouse fibroblasts. PLoS One (2012) 0.92
Human RECQ1 interacts with Ku70/80 and modulates DNA end-joining of double-strand breaks. PLoS One (2013) 0.92
PARP-mediated repair, homologous recombination, and back-up non-homologous end joining-like repair of single-strand nicks. DNA Repair (Amst) (2013) 0.90
Reduced proficiency in homologous recombination underlies the high sensitivity of embryonal carcinoma testicular germ cell tumors to Cisplatin and poly (adp-ribose) polymerase inhibition. PLoS One (2012) 0.89
DNA double strand break repair defect and sensitivity to poly ADP-ribose polymerase (PARP) inhibition in human papillomavirus 16-positive head and neck squamous cell carcinoma. Oncotarget (2015) 0.86
Re-evaluating PARP1 inhibitor in cancer. Nat Biotechnol (2011) 0.86
Tumor-selective, futile redox cycle-induced bystander effects elicited by NQO1 bioactivatable radiosensitizing drugs in triple-negative breast cancers. Antioxid Redox Signal (2014) 0.86
Probing Genome Maintenance Functions of human RECQ1. Comput Struct Biotechnol J (2013) 0.86
DNA damage in Nijmegen Breakage Syndrome cells leads to PARP hyperactivation and increased oxidative stress. PLoS Genet (2012) 0.85
Minor grove binding ligands disrupt PARP-1 activation pathways. Oncotarget (2014) 0.84
Analyzing association of the XRCC3 gene polymorphism with ovarian cancer risk. Biomed Res Int (2014) 0.84
Small-molecule collection and high-throughput colorimetric assay to identify PARP1 inhibitors. Methods Mol Biol (2011) 0.84
[(18)F]FluorThanatrace uptake as a marker of PARP1 expression and activity in breast cancer. Am J Nucl Med Mol Imaging (2016) 0.83
In vivo importance of homologous recombination DNA repair for mouse neural stem and progenitor cells. PLoS One (2012) 0.81
PARP1 expression, activity and ex vivo sensitivity to the PARP inhibitor, talazoparib (BMN 673), in chronic lymphocytic leukaemia. Oncotarget (2015) 0.80
Clinical Application of Poly(ADP-Ribose) Polymerase Inhibitors in High-Grade Serous Ovarian Cancer. Oncologist (2016) 0.80
Complex-based analysis of dysregulated cellular processes in cancer. BMC Syst Biol (2014) 0.80
Use of poly ADP-ribose polymerase [PARP] inhibitors in cancer cells bearing DDR defects: the rationale for their inclusion in the clinic. J Exp Clin Cancer Res (2016) 0.79
PET of Poly (ADP-Ribose) Polymerase Activity in Cancer: Preclinical Assessment and First In-Human Studies. Radiology (2016) 0.79
Stalled replication forks within heterochromatin require ATRX for protection. Cell Death Dis (2016) 0.79
Trial watch - inhibiting PARP enzymes for anticancer therapy. Mol Cell Oncol (2015) 0.79
Replication-induced DNA damage after PARP inhibition causes G2 delay, and cell line-dependent apoptosis, necrosis and multinucleation. Cell Cycle (2015) 0.79
Ovarian Cancers Harbour Defects in Non-Homologous End Joining Resulting in Resistance to Rucaparib. Clin Cancer Res (2016) 0.78
Hyper-active non-homologous end joining selects for synthetic lethality resistant and pathological Fanconi anemia hematopoietic stem and progenitor cells. Sci Rep (2016) 0.78
E2F-7 couples DNA damage-dependent transcription with the DNA repair process. Cell Cycle (2013) 0.78
The Novel Ribonucleotide Reductase Inhibitor COH29 Inhibits DNA Repair In Vitro. Mol Pharmacol (2015) 0.78
Strategies for the Use of Poly(adenosine diphosphate ribose) Polymerase (PARP) Inhibitors in Cancer Therapy. Biomolecules (2012) 0.78
Emerging treatment options for recurrent ovarian cancer: the potential role of olaparib. Onco Targets Ther (2013) 0.76
The Poly (ADP-Ribose) Polymerase Inhibitor Veliparib and Radiation Cause Significant Cell Line Dependent Metabolic Changes in Breast Cancer Cells. Sci Rep (2016) 0.75
PARP1 expression drives the synergistic antitumor activity of trabectedin and PARP1 inhibitors in sarcoma preclinical models. Mol Cancer (2017) 0.75
Hypoxia alters the recruitment of tropomyosins into the actin stress fibres of neuroblastoma cells. BMC Cancer (2015) 0.75
Coordinated Regulation of TIP60 and Poly(ADP-Ribose) Polymerase 1 in Damaged-Chromatin Dynamics. Mol Cell Biol (2016) 0.75
Predictors and Modulators of Synthetic Lethality: An Update on PARP Inhibitors and Personalized Medicine. Biomed Res Int (2016) 0.75
The multifaceted roles of PARP1 in DNA repair and chromatin remodelling. Nat Rev Mol Cell Biol (2017) 0.75
Berberine induces oxidative DNA damage and impairs homologous recombination repair in ovarian cancer cells to confer increased sensitivity to PARP inhibition. Cell Death Dis (2017) 0.75
Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature (2005) 19.13
Oncogene-induced senescence is part of the tumorigenesis barrier imposed by DNA damage checkpoints. Nature (2006) 11.76
DNA repair pathways as targets for cancer therapy. Nat Rev Cancer (2008) 6.69
Restoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compound. Nat Med (2002) 5.18
The cell-cycle checkpoint kinase Chk1 is required for mammalian homologous recombination repair. Nat Cell Biol (2005) 4.62
Hydroxyurea-stalled replication forks become progressively inactivated and require two different RAD51-mediated pathways for restart and repair. Mol Cell (2010) 4.57
Inhibition of human Chk1 causes increased initiation of DNA replication, phosphorylation of ATR targets, and DNA breakage. Mol Cell Biol (2005) 4.54
Recommendations for radioembolization of hepatic malignancies using yttrium-90 microsphere brachytherapy: a consensus panel report from the radioembolization brachytherapy oncology consortium. Int J Radiat Oncol Biol Phys (2007) 3.65
Identification of KIAA1018/FAN1, a DNA repair nuclease recruited to DNA damage by monoubiquitinated FANCD2. Cell (2010) 3.43
miR-182-mediated downregulation of BRCA1 impacts DNA repair and sensitivity to PARP inhibitors. Mol Cell (2010) 3.27
Pathways of mammalian replication fork restart. Nat Rev Mol Cell Biol (2010) 3.26
Spontaneous homologous recombination is induced by collapsed replication forks that are caused by endogenous DNA single-strand breaks. Mol Cell Biol (2005) 3.10
PARP is activated at stalled forks to mediate Mre11-dependent replication restart and recombination. EMBO J (2009) 2.99
Defective DNA single-strand break repair in spinocerebellar ataxia with axonal neuropathy-1. Nature (2005) 2.98
The histone methyltransferase SET8 is required for S-phase progression. J Cell Biol (2007) 2.74
Different roles for nonhomologous end joining and homologous recombination following replication arrest in mammalian cells. Mol Cell Biol (2002) 2.73
Contextual synthetic lethality of cancer cell kill based on the tumor microenvironment. Cancer Res (2010) 2.68
Methyl methanesulfonate (MMS) produces heat-labile DNA damage but no detectable in vivo DNA double-strand breaks. Nucleic Acids Res (2005) 2.44
Regulators of cyclin-dependent kinases are crucial for maintaining genome integrity in S phase. J Cell Biol (2010) 2.43
PRIMA-1Met/APR-246 induces wild-type p53-dependent suppression of malignant melanoma tumor growth in 3D culture and in vivo. Cell Cycle (2011) 2.30
PCNA on the crossroad of cancer. Biochem Soc Trans (2009) 2.03
Conservative homologous recombination preferentially repairs DNA double-strand breaks in the S phase of the cell cycle in human cells. Nucleic Acids Res (2004) 2.02
Curcumin: preventive and therapeutic properties in laboratory studies and clinical trials. Antioxid Redox Signal (2008) 1.99
Critical research gaps and translational priorities for the successful prevention and treatment of breast cancer. Breast Cancer Res (2013) 1.92
Break-induced replication repair of damaged forks induces genomic duplications in human cells. Science (2013) 1.90
Research reporting standards for radioembolization of hepatic malignancies. J Vasc Interv Radiol (2011) 1.89
Inhibition of poly (ADP-ribose) polymerase activates ATM which is required for subsequent homologous recombination repair. Nucleic Acids Res (2006) 1.88
Poly(ADP-ribose) polymerase (PARP-1) has a controlling role in homologous recombination. Nucleic Acids Res (2003) 1.86
Consumption of the putative chemopreventive agent curcumin by cancer patients: assessment of curcumin levels in the colorectum and their pharmacodynamic consequences. Cancer Epidemiol Biomarkers Prev (2005) 1.83
Pathological grading of regression following neoadjuvant chemoradiation therapy: the clinical need is now. J Clin Pathol (2012) 1.77
Essential function of Chk1 can be uncoupled from DNA damage checkpoint and replication control. Proc Natl Acad Sci U S A (2008) 1.74
Chk1 promotes replication fork progression by controlling replication initiation. Proc Natl Acad Sci U S A (2010) 1.71
Chemopreventive efficacy and pharmacokinetics of curcumin in the min/+ mouse, a model of familial adenomatous polyposis. Cancer Epidemiol Biomarkers Prev (2002) 1.69
Mre11-dependent degradation of stalled DNA replication forks is prevented by BRCA2 and PARP1. Cancer Res (2012) 1.65
A small interfering RNA screen of genes involved in DNA repair identifies tumor-specific radiosensitization by POLQ knockdown. Cancer Res (2010) 1.65
Poly (ADP-ribose) polymerase (PARP) is not involved in base excision repair but PARP inhibition traps a single-strand intermediate. Nucleic Acids Res (2010) 1.57
UV stalled replication forks restart by re-priming in human fibroblasts. Nucleic Acids Res (2011) 1.51
Overexpression of POLQ confers a poor prognosis in early breast cancer patients. Oncotarget (2010) 1.49
Poly(ADP-ribose) polymerase (PARP-1) in homologous recombination and as a target for cancer therapy. Cell Cycle (2005) 1.48
ATM is required for the cellular response to thymidine induced replication fork stress. Hum Mol Genet (2004) 1.46
PTEN deletion in prostate cancer cells does not associate with loss of RAD51 function: implications for radiotherapy and chemotherapy. Clin Cancer Res (2011) 1.46
Transcription-associated recombination is dependent on replication in Mammalian cells. Mol Cell Biol (2007) 1.45
The ERCC1/XPF endonuclease is required for efficient single-strand annealing and gene conversion in mammalian cells. Nucleic Acids Res (2007) 1.45
Ubiquitin ligase ARF-BP1/Mule modulates base excision repair. EMBO J (2009) 1.41
RAD18 and poly(ADP-ribose) polymerase independently suppress the access of nonhomologous end joining to double-strand breaks and facilitate homologous recombination-mediated repair. Mol Cell Biol (2007) 1.41
Claspin promotes normal replication fork rates in human cells. Mol Biol Cell (2008) 1.38
Reactivation of mutant p53 and induction of apoptosis in human tumor cells by maleimide analogs. J Biol Chem (2005) 1.37
RAD51 is involved in repair of damage associated with DNA replication in mammalian cells. J Mol Biol (2003) 1.36
PARP-3 is a mono-ADP-ribosylase that activates PARP-1 in the absence of DNA. J Biol Chem (2010) 1.32
Structural basis for inhibitor specificity in human poly(ADP-ribose) polymerase-3. J Med Chem (2009) 1.31
Transcription-associated recombination in eukaryotes: link between transcription, replication and recombination. Mutagenesis (2009) 1.31
The ERCC1/XPF endonuclease is required for completion of homologous recombination at DNA replication forks stalled by inter-strand cross-links. Nucleic Acids Res (2009) 1.30
6-thioguanine selectively kills BRCA2-defective tumors and overcomes PARP inhibitor resistance. Cancer Res (2010) 1.29
Liver metastases from colorectal cancer: radioembolization with systemic therapy. Nat Rev Clin Oncol (2009) 1.24
Identification of the MMS22L-TONSL complex that promotes homologous recombination. Mol Cell (2010) 1.21
Defects in homologous recombination repair in mismatch-repair-deficient tumour cell lines. Hum Mol Genet (2002) 1.19
Methylated DNA causes a physical block to replication forks independently of damage signalling, O(6)-methylguanine or DNA single-strand breaks and results in DNA damage. J Mol Biol (2010) 1.16
Ligand-induced dimerization of Drosophila peptidoglycan recognition proteins in vitro. Proc Natl Acad Sci U S A (2005) 1.16
Reduced expression of miRNA-27a modulates cisplatin resistance in bladder cancer by targeting the cystine/glutamate exchanger SLC7A11. Clin Cancer Res (2014) 1.16
Mutant p53-dependent growth suppression distinguishes PRIMA-1 from known anticancer drugs: a statistical analysis of information in the National Cancer Institute database. Carcinogenesis (2002) 1.15
ATM-mediated phosphorylation of polynucleotide kinase/phosphatase is required for effective DNA double-strand break repair. EMBO Rep (2011) 1.12
Homologous recombination repairs secondary replication induced DNA double-strand breaks after ionizing radiation. Nucleic Acids Res (2012) 1.11
Zinc binding catalytic domain of human tankyrase 1. J Mol Biol (2008) 1.09
RPA mediates recombination repair during replication stress and is displaced from DNA by checkpoint signalling in human cells. J Mol Biol (2007) 1.09
Crystal structure of human MTH1 and the 8-oxo-dGMP product complex. FEBS Lett (2011) 1.09
The role of RAD51 in etoposide (VP16) resistance in small cell lung cancer. Int J Cancer (2003) 1.09
Up-regulation of the error-prone DNA polymerase {kappa} promotes pleiotropic genetic alterations and tumorigenesis. Cancer Res (2005) 1.09
Homologous recombination repair is essential for repair of vosaroxin-induced DNA double-strand breaks. Oncotarget (2010) 1.06
Downregulation of SMG-1 in HPV-positive head and neck squamous cell carcinoma due to promoter hypermethylation correlates with improved survival. Clin Cancer Res (2012) 1.05
Targeting homologous recombination repair defects in cancer. Trends Pharmacol Sci (2010) 1.05
p53 protects from replication-associated DNA double-strand breaks in mammalian cells. Oncogene (2004) 1.04
WRN is required for ATM activation and the S-phase checkpoint in response to interstrand cross-link-induced DNA double-strand breaks. Mol Biol Cell (2008) 1.02
Inhibition of poly(ADP-ribose) glycohydrolase (PARG) specifically kills BRCA2-deficient tumor cells. Cell Cycle (2012) 1.01
Comprehensive mutational analysis of a cohort of Swedish Cornelia de Lange syndrome patients. Eur J Hum Genet (2006) 1.01
Thymidine selectively enhances growth suppressive effects of camptothecin/irinotecan in MSI+ cells and tumors containing a mutation of MRE11. Clin Cancer Res (2008) 1.00
Castration therapy results in decreased Ku70 levels in prostate cancer. Clin Cancer Res (2013) 1.00
Genome-wide linkage scan for colorectal cancer susceptibility genes supports linkage to chromosome 3q. BMC Cancer (2008) 0.99
Cohesin phosphorylation and mobility of SMC1 at ionizing radiation-induced DNA double-strand breaks in human cells. Exp Cell Res (2010) 0.99